D745 + D150

D745 + D150 is a **combination therapy of two investigational oral agents** developed by Chong Kun Dang Pharmaceutical, primarily studied for the treatment of type 2 diabetes. Both agents are designated by code numbers (D745 and D150) and are used together in several clinical pharmacology and efficacy studies primarily in South Korea. Their individual active pharmaceutical ingredients or pharmacologic classes are not specified in publicly available sources. The combination is studied for its effects on glycemic control, particularly in subjects not adequately managed by existing regimens, often as a comparator in studies evaluating additional agents such as CKD-501 or CKD-383. Both D745 and D150 appear to be oral small molecules with unknown specific mechanisms. The combination is administered orally and studied for safety and pharmacokinetics in healthy subjects and for efficacy in diabetic patients[1][2][3][4][6].